Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Exclusion Criteria

• •Ejection fraction (EF) below 30% at screening
• •Progressive angina with symptoms of worsening of angina within the \<3 month
• •History of recent myocardial infarction or unstable Angina
• •Documented current relevant coronary stenosis ≥90% in any of the main 3 coronary vessels without bypass graft
• •Symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months or patients with stroke at more than 3 months
• •Insulin dependent diabetes mellitus
• •Clinically significant and persisting cardiac ischemia
• •Atrial fibrillation, pacemaker, defibrillator, second and third degree atrial-ventricular (AV) block
• •Known clinically relevant ventricular arrhythmias
• •Clinically relevant heart failure with reduced left ventricular ejection fraction
• •Significant valvular heart disease with moderate or severe aortic stenosis or any other significant stenosis; any other moderate or severe valvular failures
• •Valve replacement
• •Hypertrophic obstructive cardiomyopathy (HOCM)
• •Previous or imminent cardiac transplantation
• •Known long QT syndrome or prolongation of the QT interval with ongoing proarrhythmic conditions
• •Co-medication with drugs known to have QT prolonging effect
• •Intolerance of fluoroquinolones, including moxifloxacin
• •History of serious adverse effects e.g. tendinitis and tendon rupture, arthralgia and effects on the peripheral and central nervous system while taking fluoroquinolones including moxifloxacin
• •History of tendon diseases or tendon injury caused by quinolones
• •Treatment with fluoroquinolones, including moxifloxacin during the last 2 weeks
• •Treatment with organic nitrates during the last 3 months
• •Treatment with riociguat during the last 3 months
• •Treatment with phosphodiesterase (PDE)-5 inhibitors during the last 14 days
• •Systolic blood pressure below 110 or above 160 mmHg at screening visit
• •Diastolic blood pressure below 50 or above 100 mmHg at screening visit
• •Heart rate below 50 or above 100 beats/min (taken from ECG measurement) at first screening visit
• •Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m\*2